BCL11A and Schnyder corneal dystrophy: CRISPR/Cas9 is used to disturb the erythroid-specific enhancer for the BCL11A gene ex vivo in hematopoietic stem cells, which ultimately leads to an increase in HbF and supports the treatment of SCD and β-thalassemia.